[Journal of Pediatric Endocrinology and Metabolism] Endocrine consequences of neuroblastoma treatment in children 20 years experience of a single center.pdf
[en] Background: Neuroblastoma (NBL) is a child neoplasia affecting extracranial tissue of neuroectodermal origin. It accounts for 10% of solid malignancies in children and is characterized by a survival rate approaching 70%, confronting physicians with the emergence of an adult survivor population who have been previously exposed to surgery, cytotoxic drugs, radiation therapy or metaio- dobenzylguanidine (MIBG) therapy. All these treatments potentially affect the endocrine system. Our study consists in a retrospective review of late endocrine effects arising in survivors treated for NBL during childhood.
Methods: The medical files of 47 patients (M/F = 26/21) treated for NBL were reviewed. Collected data consisted of age, height, weight and biological hormonal values at diagnosis and at the last follow-up consultation. The inci- dence of late effects in our sample was compared to the data from the literature.
Results: Patients were between 0 and 15.8 years of age at diagnosis (median: 1.16 years) and between 1 and 25 years of age at last follow-up (median: 16 years). Twenty-six patients were treated with chemotherapy (CT), 11 under- went CT and radiation therapy and five were treated with CT and MIBG therapy. Ten percent of the patients died before reaching the end of therapy. Late effects occurred in 54% of the patients. Thirty-six percent of patients had non-endocrine complications (musculoskeletal, neuro- logical, hematological or hepatic chronic conditions). Endocrine complications (28%) affected mainly patients treated with CT and consisted of gonadal dysfunction (up to 42% patients of over 12 years of age at follow-up) and hypothyroidism (21%). Our analysis revealed that CT had a significant impact on final height (p < 0.05). Conclusions: Treatment for childhood malignancies exposes children to late effects affecting the endocrine sys- tem. In children treated for NBL, hypothyroidism, gonadal failure and impaired growth appear to be the main endo- crine complications. Close follow-up of survivors is thus appropriate.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Geurten, Claire ; Centre Hospitalier Universitaire de Liège - CHU > Département de Pédiatrie > Service de pédiatrie
Geurten, Marie ; Université de Liège - ULiège > Département de Psychologie > Neuroimagerie des troubles de la mémoire et revalid. cogn.
HOYOUX, Claire ; Centre Hospitalier Universitaire de Liège - CHU > Département de Pédiatrie > Service de pédiatrie
LEBRETHON, Marie-Christine ; Centre Hospitalier Universitaire de Liège - CHU > Département de Pédiatrie > Centre de l'obésité de l'enfant - adolescent
Language :
English
Title :
Endocrine consequences of neuroblastoma treatment in children: 20 years’ experience of a single center
Parikh NS, Howard SC, Chantada G, Israels T, Khattab M, et al. Clinical practice guidelines-SIOP-PODC adapted risk stratification and treatment guidelines: recommendations for neuroblastoma in low-and middle-income settings. Pediatr Blood Cancer 2015;62:1305-16.
Cohen LE, Gordon JH, Popovsky EY, Gunawardene S, Duffey-Lind E, et al. Late effects in children treated with intensive multimodal therapy fo high-risk neuroblastoma: high incidence of endocrine and growth problems. BMT 2014;49:502-8.
Quach A, Ji L, Mishra V, Sznewajs A, Veatch J, et al. Thyroid and hepatic function after high-dose 131I-metaiodobenzylguanidine (131I-MIBG) therapy for neuroblastoma. Pediatr Blood Cancer 2011;56:191-201.
SIOPEN RNET. European Low and Intermediate Risk Neuroblastoma Protocol: A SIOPEN Study, version 4.2. Available at: http://sfce.sfpediatrie.com/sites/default/files/LINES-Protocol-version-4.2-2-janvier-2013-01.pdf. Accessed 17 Feb 2019.
SIOPEN RNET. High Risk Neuroblastoma Study 1.7 of SIOP-Europe (SIOPEN). Available at: http://sfce.sfpediatrie.com/sites/default/files/hrnbl1-7-protocol-r4-randomisation-juni-2014.pdf. Accessed 17 Feb 2019.
Dickerman JD. The late effects of childhood cancer therapy. Pediatrics 2007;119:554-68.
Laverdière C, Liu Q, Yasui Y, Nathan PC, Gurney JG, et al. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009;101:1131-40.
Nandogopal R, Laverdière C, Mulrroney D, Hudson MM, Meacham L. Endocrine late effects of childhood cancer therapy: a report from the Children's Oncology Group. Horm Res 2008;69:65-74.
Monzani A, Prodam F, Rapa A, Moia A, Agarla V, et al. Natural history of subclinical hypothyroidism in children and adolescents and potential effects of replacement therapy: a review. Eur J Endocrinol 2013;168:R1-11.
Van Santen HM, de Kraker J, Vulsma T. Endocrine late effects from multi-modality treatment of neuroblastoma. Eur J Endocrinol 2005;41:1767-74.
Goswami D, Conway GS. Premature ovarian failure. Horm Res 2007;68:196-202.
Stukenborg J-B, Jahnukainen K, Hutka M, Mitchell RT. Cancer treatment in childhood and testicular function: the importance of the somatic environment. Endocr Connect 2018;7:R69-87.
Knijnenburg SL, Raemaekers S, van den Berg H, van Dijk IW, Lieverst JA, et al. Final height in survivors of childhood cancer compared with height standard deviation scores at diagnosis. Ann Oncol 2013;24:1119-26.
Hobbie WL, Mostoufi S, Carlson CA, Gruccio D, Ginsberg JP. Prevalence of advanced bone age in a cohort of patients who received cis-retinoic acid for high-risk neuroblastoma. Pediatr. Blood Cancer 2011;56:474-6.